• Arch Biopartners engaged a U.S. bioengineering laboratory to accelerate its pre-IND IL-32 chronic kidney disease program.
• Work aims to generate proprietary studies to support patent filings covering IL-32 drug candidates and related method-of-use claims.
• Program targets diabetic kidney disease, supported by human tissue findings and disease models linking IL-32 to inflammation and tubular injury.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607170820PRIMZONEFULLFEED9763856) on July 17, 2026, and is solely responsible for the information contained therein.